Actavis Loss In ADHD Drug IP Fight Backed By Fed. Circ.
The Federal Circuit has upheld a ruling from Delaware's top federal judge that found a Teva unit failed to show three patents on the ADHD treatment Quillivant XR were invalid, finding...To view the full article, register now.
Already a subscriber? Click here to view full article